Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Mylan
Emtricitabine/Tenofovir disoproxil Mylan 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19–20
HOS-134249 · Präparat HOS-097542
19 Medicinal product by Effects on drug Recommendation concerning therapeutic areas levels co-administration with Mean percent emtricitabine/tenofovir disoproxil change in AUC, (emtricitabine 200 mg, tenofovir disoproxil Cmax, Cmin with 245 mg) 90% confidence intervals if available (mechanism) Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations of tenofovir (400 mg/100 mg q.d.) + AUC: ↓ 28% (↓ 34 resulting from co-administration of tenofovir Darunavir/Ritonavir to ↓ 20) disoproxil, sofosbuvir/velpatasvir and (800 mg q.d./100 mg q.d.) + Cmax: ↓ 38% (↓ 46 darunavir/ritonavir may increase adverse Emtricitabine/Tenofovir disoproxil (200 mg/245 mg q.d.) to ↓ 29) reactions related to tenofovir disoproxil, including renal disorders. The safety of GS-3310072: tenofovir disoproxil when used with AUC: ↔ sofosbuvir/velpatasvir and a pharmacokinetic Cmax: ↔ enhancer (e.g. ritonavir or cobicistat) has not Cmin: ↔ been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-03T14:25:00Z · SHA-256 dca28001b5f37f5fac24ef504bb45938e413f238844fb60b012f3f9b5a32b40c · Passage 0a7fc6e8fd6601fb448afb3fbb102cb3a136390494ac0a139bc59d7ccfb0a0e8 · Zeichen 27113–28799 im Abschnitt